Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.65 |
| ▸ | JAK3 | P52333 | 17/20 | 0.56 |
| ▸ | JAK1 | P23458 | 15/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566667 | 1.00 | NUDT1 (0.65) | NUDT1JAK3JAK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29477135 | 0.99 | NUDT1 (0.64) | NUDT1JAK3JAK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29234028 | 0.99 | NUDT1 (0.64) | NUDT1JAK3JAK1MEN1KMT2A | |
| SCHEMBL20956287 | 0.90 | NUDT1 (0.52) | NUDT1JAK3JAK1MEN1KMT2A | |
| SCHEMBL2115690 | 0.86 | AXL (0.55) | NUDT1JAK3JAK1AXLPRKCI | |
| SCHEMBL30985188 | 0.86 | AXL (0.55) | NUDT1JAK3JAK1AXLPRKCI | |
| SCHEMBL20956013 | 0.86 | JAK3 (0.50) | NUDT1JAK3JAK1MEN1KMT2A | |
| SCHEMBL31120987 | 0.86 | JAK3 (0.50) | NUDT1JAK3JAK1MEN1KMT2A | |
| SCHEMBL12876122 | 0.84 | NUDT1 (0.47) | NUDT1JAK3JAK1MEN1KMT2A | |
| SCHEMBL12887787 | 0.84 | NUDT1 (0.47) | NUDT1JAK3JAK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038910-A1 | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHODS FOR ITS PREPARATION | ACLARIS THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| CN-119119039-A | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-111566095-B | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-116583281-A | Crystalline polymorph form a of JAK inhibitor and methods for its preparation | 阿克拉瑞斯治疗股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4216953-A1 | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHODS FOR ITS PREPARATION | Aclaris Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | ACLARIS THERAPEUTICS, INC. | 2022-08-23 | — | — | US | disclosed |
| WO-2022067106-A1 | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHODS FOR ITS PREPARATION | ACLARIS THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420966-B2 | Substituted pyrrolopyridines as JAK inhibitors | JAK1, JAK3, JAK2 | NUDT1 3467/4885JAK3 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.